Diabetes (Insulin-requiring, Type 1 or Type 2)NCT07392853
Investigation of the Effectiveness of Prophylactic NPWT (ciNPWT) in High-risk Diabetic Patients With Acute Laparotomy Wounds
A study testing Prophylactic/Incisional Negative Pressure Wound Therapy in people with Diabetes (Insulin-requiring, Type 1 or Type 2), run by Semmelweis University at 1 site in Hungary.
Trial summary
The aim of this study is to evaluate the effectiveness of prophylactic Negative Pressure Wound Therapy (NPWT) in patients with diabetes mellitus undergoing laparotomy who are at high risk for Surgical Site Infections (SSI). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Diabetes (Insulin-requiring, Type 1 or Type 2)
- What is being tested?
- Prophylactic/Incisional Negative Pressure Wound Therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 110 participants
- Where
- 1 siteHungary
- Study dates
- 22 Feb 2026to 22 Mar 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Pregnancy,
- Disseminated cancer (irresectable distant metastasis, peritoneal carcinomatosis),
- Life expectancy of less than 30 days,
- Refusal to participate in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hungary1 site
Semmelweis University, Department of Surgery, Transplantation and Gastroenterology
Budapest, 1082
Balazs Banky, +36-20-825-8915, bankybalazs@gmail.com
Andras Herczeg, +36-20-670-1721, herczeg.andras.ivan@semmelweis.hu
About this study
Official title: Investigation of the Effectiveness of Prophylactic NPWT (ciNPWT) in High-risk Diabetic Patients With Acute Laparotomy Wounds - A Randomized, Prospective Clinical Trial
The aim of this study is to evaluate the effectiveness of prophylactic Negative Pressure Wound Therapy (NPWT) in patients with diabetes mellitus undergoing laparotomy who are at high risk for Surgical Site Infections (SSI). In addition to clinical efficacy, the investigators also plan a cost effectiveness analysis to assess the applicability of this relatively high-cost intervention in a domestic healthcare setting.
Read the detailed description
Background and Introduction Postoperative surgical site infections (SSI) continue to represent a significant challenge across almost all surgical disciplines, despite the widespread implementation of well-established aseptic and preventive measures. Abdominal surgery, in particular, presents an inherently higher risk, considering the nature of the procedures (e.g., surgeries involving bowel resections). For emergency and urgent procedures, the rate of wound infections can reach as high as 30%, according to some literature sources.
Risk Factors for SSI Risk factors can be categorized based on the surgical procedure itself (e.g., acute/elective, bowel resection/non-resection, wound cleanliness), patient characteristics (e.g., diabetes, smoking, peripheral arterial disease, obesity, age, gender), underlying medical conditions (e.g., cancer, immunosuppressed or septic patients), and perioperative management (e.g., surgical duration, transfusion requirements, hypothermia, hyper/hypoglycemia, hypoxia, pharmacological treatments). Many of these factors are modifiable during patient care (e.g., achieving normothermia, ensuring proper asepsis during surgery, maintaining normoglycemia) or preoperatively (e.g., improving nutritional status, correcting anemia, managing chronic diseases such as diabetes and hypertension, promoting weight reduction). However, in emergency surgeries, there is often insufficient time to address these factors, significantly increasing the risk of SSI.
The Impact of Diabetes Mellitus as an SSI Risk Factor Uncontrolled diabetes is associated with a higher incidence of complications, including wound infections. Factors such as tissue hypoxia (due to diabetic micro- and macroangiopathy and impaired angiogenesis), cellular dysfunction (e.g., abnormal endothelial, macrophage, and neutrophil function), and the formation of glycotoxins (Advanced Glycation End-products or AGEs) due to hyperglycemia impair wound healing. Numerous large-scale meta-analyses have confirmed the association between diabetes and surgical wound infections . Studies across various surgical fields (e.g., cardiac surgery, orthopedics, colorectal surgery) have demonstrated that preoperative (HbA1c) and perioperative (normoglycemia) management of blood glucose levels can significantly reduce the risk of SSI .
ciNPWT (Closed Incisional, Prophylactic NPWT) as a Method for Preventing Surgical Site Infections
Negative Pressure Wound Therapy (NPWT) was initially developed in the 1990s to treat chronic, difficult-to-heal wounds (Argenta \& Morykwas). The mechanism of NPWT involves the application of either continuous or intermittent negative pressure, which increases tissue vascularization, reduces edema, and promotes wound healing by removing necrotic tissue debris and stimulating granulation tissue formation. When applied prophylactically to closed surgical incisions, the available literature supports the significant reduction of septic surgical complications. Based on the results of a previously published multicenter, randomized, prospective clinical trial conducted by the investigators' research team, ciNPWT has been shown to reduce the incidence of SSIs following high-risk, urgent general abdominal surgeries (2). However, in that study, few poorly controlled diabetic patients were included, meaning no conclusions could be drawn specifically regarding this high-risk group. The effectiveness of NPWT has been largely settled in clinical debate, with numerous studies demonstrating its positive impact on wound healing. However, the cost-effectiveness of prophylactic NPWT remains an open question.
- Being tested
- Prophylactic/Incisional Negative Pressure Wound Therapy
- Keywords
- abdominal surgery, SSI, diabetes, emergency surgery, ciNPWT
- Medical subject headings
- Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prophylactic/Incisional Negative Pressure Wound TherapyDevice
Negative Pressure Wound Therapy device used on closed laparotomy wound to prevent SSI.
| Study group | Role | What they receive |
|---|---|---|
| ciNPWT | Experimental | Group of patients being treated with prophylactic NPWT after emergency laparotomy. Receives: Device: Prophylactic/Incisional Negative Pressure Wound Therapy |
| Control | No intervention | Group of patients being treated with "regular" wound dressing. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of SSI
The ratio of patients developing surgical site infection after emergency laparotomy.
Unit of Measure: Number and percentage of patients Measurement Tool : Clinical assessment and medical records
Measured: 30 days
Secondary outcomes (7)
Length of Intensive Care Unit (ICU) stay
Number of days spent in the Intensive Care Unit following surgery. Unit of Measure: Days Measurement Tool: Hospital medical records
Measured: 30 days
Length of hospital stay
Total number of days of hospitalization following surgery.
Unit of Measure: Days Measurement Tool: Hospital medical records
Measured: 30 days
Incidence of abdominal wall dehiscence
Occurrence of abdominal wall dehiscence following surgery.
Unit of Measure: Number and percentage of patients Measurement Tool : Clinical assessment and medical records
Measured: 30 days
Reoperation rate
Proportion of patients requiring at least one reoperation following the index procedure.
Unit of Measure: Number and percentage of patients (Yes/No)
Measurement Tool: medical records
Measured: 30 days
Number of reoperations per patient
Total number of reoperations performed per patient during the study period.
Unit of Measure: Count
Measurement Tool: medical records
Measured: 30 days
Quality of life assessed by EQ-5D questionnaire
Health-related quality of life assessed using the EQ-5D questionnaire.
Unit of Measure: Score
Measurement Tool: EQ-5D questionnaire
Measured: 30 days
Direct healthcare costs
Direct healthcare costs associated with postoperative care and complications.
Unit of Measure: Hungarian Forint (HUF)
Measurement Tool: Hospital billing and accounting records
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2026
- Study start22 Feb 2026 (estimated)
- Primary completion22 Feb 2026 (estimated)
- Study completion22 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes (Insulin-requiring, Type 1 or Type 2)Studies of the same condition, open and under way.
- More trials run by Semmelweis UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 110 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Semmelweis University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Herczeg András, Semmelweis University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07392853
- Sponsor's protocol ID
- BM/30843-3/2025
- Status last verified
- Jan 2026
- First submitted
- 24 Jan 2026
- Last updated
- 6 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We apply strict regulations for the secure handling of IPD during the study. The data are used solely for the purposes of the research, and sharing them with other researchers could increase privacy risks.
Study at a glance
From the registry record, last updated by the sponsor on 6 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Effectiveness of Prophylactic NPWT (ciNPWT) in High-risk Diabetic Patients With Acute Laparotomy Wounds - A Randomized, Prospective Clinical Trial
- ClinicalTrials.gov ID
- NCT07392853
- Acronym / sponsor ID
- BM/30843-3/2025
- Keywords
- abdominal surgery, SSI, diabetes, emergency surgery, ciNPWT
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 110 participants (estimated)
- Lead sponsor
- Semmelweis UniversityUniversity, hospital or other
- Study start
- 22 Feb 2026 (estimated)
- Primary completion
- 22 Feb 2026 (estimated)
- Study completion
- 22 Mar 2026 (estimated)
- First posted
- 6 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the effectiveness of prophylactic Negative Pressure Wound Therapy (NPWT) in patients with diabetes mellitus undergoing laparotomy who are at high risk for Surgical Site Infections (SSI). In addition to clinical efficacy, the investigators also plan a cost effectiveness analysis to assess the applicability of this relatively high-cost intervention in a domestic healthcare setting.
Detailed description
Background and Introduction Postoperative surgical site infections (SSI) continue to represent a significant challenge across almost all surgical disciplines, despite the widespread implementation of well-established aseptic and preventive measures. Abdominal surgery, in particular, presents an inherently higher risk, considering the nature of the procedures (e.g., surgeries involving bowel resections). For emergency and urgent procedures, the rate of wound infections can reach as high as 30%, according to some literature sources.
Risk Factors for SSI Risk factors can be categorized based on the surgical procedure itself (e.g., acute/elective, bowel resection/non-resection, wound cleanliness), patient characteristics (e.g., diabetes, smoking, peripheral arterial disease, obesity, age, gender), underlying medical conditions (e.g., cancer, immunosuppressed or septic patients), and perioperative management (e.g., surgical duration, transfusion requirements, hypothermia, hyper/hypoglycemia, hypoxia, pharmacological treatments). Many of these factors are modifiable during patient care (e.g., achieving normothermia, ensuring proper asepsis during surgery, maintaining normoglycemia) or preoperatively (e.g., improving nutritional status, correcting anemia, managing chronic diseases such as diabetes and hypertension, promoting weight reduction). However, in emergency surgeries, there is often insufficient time to address these factors, significantly increasing the risk of SSI.
The Impact of Diabetes Mellitus as an SSI Risk Factor Uncontrolled diabetes is associated with a higher incidence of complications, including wound infections. Factors such as tissue hypoxia (due to diabetic micro- and macroangiopathy and impaired angiogenesis), cellular dysfunction (e.g., abnormal endothelial, macrophage, and neutrophil function), and the formation of glycotoxins (Advanced Glycation End-products or AGEs) due to hyperglycemia impair wound healing. Numerous large-scale meta-analyses have confirmed the association between diabetes and surgical wound infections . Studies across various surgical fields (e.g., cardiac surgery, orthopedics, colorectal surgery) have demonstrated that preoperative (HbA1c) and perioperative (normoglycemia) management of blood glucose levels can significantly reduce the risk of SSI .
ciNPWT (Closed Incisional, Prophylactic NPWT) as a Method for Preventing Surgical Site Infections
Negative Pressure Wound Therapy (NPWT) was initially developed in the 1990s to treat chronic, difficult-to-heal wounds (Argenta \& Morykwas). The mechanism of NPWT involves the application of either continuous or intermittent negative pressure, which increases tissue vascularization, reduces edema, and promotes wound healing by removing necrotic tissue debris and stimulating granulation tissue formation. When applied prophylactically to closed surgical incisions, the available literature supports the significant reduction of septic surgical complications. Based on the results of a previously published multicenter, randomized, prospective clinical trial conducted by the investigators' research team, ciNPWT has been shown to reduce the incidence of SSIs following high-risk, urgent general abdominal surgeries (2). However, in that study, few poorly controlled diabetic patients were included, meaning no conclusions could be drawn specifically regarding this high-risk group. The effectiveness of NPWT has been largely settled in clinical debate, with numerous studies demonstrating its positive impact on wound healing. However, the cost-effectiveness of prophylactic NPWT remains an open question.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ciNPWT | Experimental | Device: Prophylactic/Incisional Negative Pressure Wound TherapyGroup of patients being treated with prophylactic NPWT after emergency laparotomy. |
| Control | No intervention | –Group of patients being treated with "regular" wound dressing. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (4 listed)
- Pregnancy,
- Disseminated cancer (irresectable distant metastasis, peritoneal carcinomatosis),
- Life expectancy of less than 30 days,
- Refusal to participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prophylactic/Incisional Negative Pressure Wound TherapyNegative Pressure Wound Therapy device used on closed laparotomy wound to prevent SSI. | Device | ciNPWT |
Primary outcome
Incidence of SSI
Time frame: 30 days
The ratio of patients developing surgical site infection after emergency laparotomy. Unit of Measure: Number and percentage of patients Measurement Tool : Clinical assessment and medical records
7 secondary outcomes
Length of Intensive Care Unit (ICU) stay
Time frame: 30 days
Length of hospital stay
Time frame: 30 days
Incidence of abdominal wall dehiscence
Time frame: 30 days
Reoperation rate
Time frame: 30 days
Number of reoperations per patient
Time frame: 30 days
Quality of life assessed by EQ-5D questionnaire
Time frame: 30 days
Direct healthcare costs
Time frame: 30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Feb 2026.
- Individual participant dataSharing planned: No. We apply strict regulations for the secure handling of IPD during the study. The data are used solely for the purposes of the research, and sharing them with other researchers could increase privacy risks.
Related trials for Diabetes (Insulin-requiring, Type 1 or Type 2)
Not yet recruiting
A Novel Miniature Equine-Assisted Diabetes Education Program for Youth: Evaluating the Diabetes Equine Empowerment Program (DEEP).
Diabetes (Insulin-requiring, Type 1 or Type 2), Pediatric Diabetes
Not yet recruiting
Safety and Efficacy of the Fully Closed Loop iLet Bionic Pancreas in Adults With Type 1 and Type 2 Diabetes
Diabetes (Insulin-requiring, Type 1 or Type 2)
Recruiting
Integrating New Skills Into Diabetes Education With CGM
Insulin Dependent Diabetes, Diabetes (DM)
Recruiting
Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)
Diabetes (Insulin-requiring, Type 1 or Type 2)
RecruitingObservational study
Benefits of Retained Insulin for Good Health
Diabetes (Insulin-requiring, Type 1 or Type 2), Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Prophylactic/Incisional Negative Pressure Wound Therapy in people with Diabetes (Insulin-requiring, Type 1 or Type 2), run by Semmelweis University at 1 site in Hungary.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hungary. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Balázs Bánky (+36-20-825-8915, bankybalazs@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of SSI (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2026.